2023
Coffee, adenosine, and the liver
Dranoff J. Coffee, adenosine, and the liver. Purinergic Signalling 2023, 20: 21-28. PMID: 37755557, PMCID: PMC10828332, DOI: 10.1007/s11302-023-09968-5.Peer-Reviewed Original Research
2017
Coffee Consumption and Prevention of Cirrhosis: In Support of the Caffeine Hypothesis
Dranoff JA. Coffee Consumption and Prevention of Cirrhosis: In Support of the Caffeine Hypothesis. Gene Expression 2017, 18: 1-3. PMID: 28893365, PMCID: PMC5885142, DOI: 10.3727/105221617x15046391179559.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsAn Elf2-like transcription factor acts as repressor of the mouse ecto-5′-nucleotidase gene expression in hepatic myofibroblasts
Fausther M, Lavoie EG, Goree JR, Dranoff JA. An Elf2-like transcription factor acts as repressor of the mouse ecto-5′-nucleotidase gene expression in hepatic myofibroblasts. Purinergic Signalling 2017, 13: 417-428. PMID: 28667437, PMCID: PMC5714833, DOI: 10.1007/s11302-017-9570-7.Peer-Reviewed Original ResearchConceptsLiver myofibroblastsHepatic fibrosisChronic liver injuryNon-parenchymal liver cellsTissue repair processEffector cellsLiver injuryLiver fibrosisHepatic myofibroblastsMyofibroblast functionContractile propertiesPathological wound healingExtracellular adenosineMyofibroblastsImportant mediatorPromoter transcriptional activityFibrosisLiver cellsGene expressionWound healingEndogenous moleculesImportant regulatorHeterogeneous populationLocal microenvironmentFactor acts
2015
I drink for my liver, Doc: emerging evidence that coffee prevents cirrhosis
Feld JJ, Lavoie ÉG, Fausther M, Dranoff JA. I drink for my liver, Doc: emerging evidence that coffee prevents cirrhosis. F1000Research 2015, 4: 95. PMID: 25977756, PMCID: PMC4416533, DOI: 10.12688/f1000research.6368.2.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsChronic liver diseaseSalutary effectsLiver diseaseLiver fibrosisHepatocellular carcinomaNovel pharmacologic treatmentsCoffee ingestionPharmacologic treatmentFibrosis pathogenesisObservational studyRegular ingestionCoffee consumptionEpidemiological dataPharmacological effectsCaffeine consumptionCirrhosisDecaffeinated coffeeCaffeine effectsEffector moleculesPatientsFibrosisPathogenesisDiseaseIngestionConsistent effectStrategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014
Torok NJ, Dranoff JA, Schuppan D, Friedman SL. Strategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014. Hepatology 2015, 62: 627-634. PMID: 25626988, PMCID: PMC4515973, DOI: 10.1002/hep.27720.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsClinical trial designTrial designLiver diseaseLiver fibrosisClinical trialsFuture clinical trial designChronic liver diseaseOff-target toxicityKey unmetPotential off-target toxicityAntifibrotic agentsNoninvasive markerAntifibrotic therapyAntifibrotic drugsPreclinical proofDrug trialsStudy groupRisk populationsPharmacological targetsTrialsExpert overviewFibrosisDiseaseEndpointAmerican AssociationI drink for my liver, Doc: emerging evidence that coffee prevents cirrhosis
Feld J, Lavoie É, Fausther M, Dranoff J. I drink for my liver, Doc: emerging evidence that coffee prevents cirrhosis. F1000Research 2015, 4: 95. DOI: 10.12688/f1000research.6368.1.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsChronic liver diseaseSalutary effectsLiver diseaseLiver fibrosisHepatocellular carcinomaNovel pharmacologic treatmentsCoffee ingestionPharmacologic treatmentFibrosis pathogenesisObservational studyRegular ingestionCoffee consumptionEpidemiological dataPharmacological effectsCaffeine consumptionCirrhosisDecaffeinated coffeeCaffeine effectsEffector moleculesPatientsFibrosisPathogenesisDiseaseIngestionConsistent effect
2014
MCP‐1 downregulates MMP‐9 export via vesicular redistribution to lysosomes in rat portal fibroblasts
Hickman DA, Syal G, Fausther M, Lavoie EG, Goree JR, Storrie B, Dranoff JA. MCP‐1 downregulates MMP‐9 export via vesicular redistribution to lysosomes in rat portal fibroblasts. Physiological Reports 2014, 2: e12153. PMID: 25413315, PMCID: PMC4255798, DOI: 10.14814/phy2.12153.Peer-Reviewed Original ResearchHow does coffee prevent liver fibrosis? biological plausibility for recent epidemiological observations
Dranoff JA, Feld JJ, Lavoie É, Fausther M. How does coffee prevent liver fibrosis? biological plausibility for recent epidemiological observations. Hepatology 2014, 60: 464-467. PMID: 24464631, PMCID: PMC4110162, DOI: 10.1002/hep.27032.Peer-Reviewed Original Research
2013
Posttranslational regulation of tissue inhibitor of metalloproteinase‐1 by calcium‐dependent vesicular exocytosis
Dranoff JA, Bhatia N, Fausther M, Lavoie EG, Granell S, Baldini G, Hickman DA, Sheung N. Posttranslational regulation of tissue inhibitor of metalloproteinase‐1 by calcium‐dependent vesicular exocytosis. Physiological Reports 2013, 1: e00125. PMID: 24400134, PMCID: PMC3871447, DOI: 10.1002/phy2.125.Peer-Reviewed Original ResearchHepatic stellate cellsMyofibroblastic hepatic stellate cellsLiver fibrosisMetalloproteinase-1Tissue inhibitorVesicular exocytosisTIMP-1 releaseLiver myofibroblastsStellate cellsTIMP-1FibrosisCritical mediatorNew targetsInhibitorsPosttranslational regulationFibrinolysisExocytosisMyofibroblastsReleaseContribution of Myofibroblasts of Different Origins to Liver Fibrosis
Fausther M, Lavoie EG, Dranoff JA. Contribution of Myofibroblasts of Different Origins to Liver Fibrosis. Current Pathobiology Reports 2013, 1: 225-230. PMID: 23997993, PMCID: PMC3755779, DOI: 10.1007/s40139-013-0020-0.Peer-Reviewed Original ResearchHepatic fibrosisLiver fibrosisLiver myofibroblastsContribution of myofibroblastsProgressive liver fibrosisPrimary effector cellsTissue repair responseExtracellular matrix accumulationMajor fibrogenic cellsLiver failureLiver injuryEffector cellsCurrent therapiesAntifibrotic therapyCommon causeScar formationFibrogenic cellsFibrosisMatrix accumulationExtracellular matrix synthesisMyofibroblastsPromising targetWound healingRepair responseTherapy
2009
Portal fibroblasts: Underappreciated mediators of biliary fibrosis
Dranoff JA, Wells RG. Portal fibroblasts: Underappreciated mediators of biliary fibrosis. Hepatology 2009, 51: 1438-1444. PMID: 20209607, PMCID: PMC2850946, DOI: 10.1002/hep.23405.Peer-Reviewed Original ResearchConceptsPortal fibroblastsNonparenchymal cell populationBiliary fibrosisStellate cellsCell populationsHepatic stellate cellsFibrogenic myofibroblastsChronic injuryBiliary epitheliumDuct epitheliumFibrotic liverUnderappreciated mediatorCollagen productionFurther studiesFibrosisLiverEpitheliumFibroblastsCellsFibrogenesisInjuryPopulationMyofibroblastsPathobiologyImportant roleIntracellular calcium signals regulate growth of hepatic stellate cells via specific effects on cell cycle progression
Soliman EM, Rodrigues MA, Gomes DA, Sheung N, Yu J, Amaya MJ, Nathanson MH, Dranoff JA. Intracellular calcium signals regulate growth of hepatic stellate cells via specific effects on cell cycle progression. Cell Calcium 2009, 45: 284-292. PMID: 19131107, PMCID: PMC3018528, DOI: 10.1016/j.ceca.2008.11.006.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCalcium SignalingCalcium-Calmodulin-Dependent Protein Kinase Type 2Cdc25 PhosphatasesCell CompartmentationCell CycleCell NucleusCell ProliferationChelating AgentsCytosolEgtazic AcidEnzyme InhibitorsG2 PhaseHepatocytesHumansIntracellular SpaceParvalbuminsPhosphorylationProtein TransportRatsSubcellular FractionsConceptsHepatic stellate cellsLiver fibrosisStellate cellsImmortalized human hepatic stellate cellsHSC growthHuman hepatic stellate cellsRat hepatic stellate cellsPrimary rat hepatic stellate cellsIntracellular calcium signalsCdc25C phosphorylationPharmacological therapyCalmodulin kinase IIImportant mediatorCell cycle progressionHSC proliferationCell proliferationLogical targetCalcium signalsAdenoviral constructDownstream intracellularG2/M checkpointCaMK IIFibrosisBlockadeParvalbumin
2007
Molecular basis for calcium signaling in hepatic stellate cells
Kruglov EA, Correa PR, Arora G, Yu J, Nathanson MH, Dranoff JA. Molecular basis for calcium signaling in hepatic stellate cells. AJP Gastrointestinal And Liver Physiology 2007, 292: g975-g982. PMID: 17204544, DOI: 10.1152/ajpgi.00401.2006.Peer-Reviewed Original ResearchMeSH KeywordsActive Transport, Cell NucleusAdenosine TriphosphateAnimalsCalcium SignalingCalreticulinCell NucleusCell ShapeCell Surface ExtensionsCells, CulturedEndoplasmic ReticulumInositol 1,4,5-Trisphosphate ReceptorsLiverLiver CirrhosisMaleMicroscopy, ConfocalMicroscopy, VideoRatsRats, Sprague-DawleyReceptors, Purinergic P2RNA, MessengerTime FactorsConceptsHepatic stellate cellsCell extensionsLipid-storing cellsSubcellular organizationLiver fibrosisMolecular basisStellate cellsSubcellular signalingTrisphosphate receptorChronic liver failureProgressive liver fibrosisSufficient machineryExtracellular ATPMyofibroblastic transdifferentiationOrgan fibrosisLiver failureP2Y receptorsHealthy liverATPLocal controlCellsCritical stepLocal applicationImportant mediatorFibrosisPrevention of liver fibrosis by the purinoceptor antagonist pyridoxal-phosphate-6-azophenyl-2',4'-disulfonate (PPADS).
Dranoff JA, Kruglov EA, Abreu-Lanfranco O, Nguyen T, Arora G, Jain D. Prevention of liver fibrosis by the purinoceptor antagonist pyridoxal-phosphate-6-azophenyl-2',4'-disulfonate (PPADS). In Vivo 2007, 21: 957-65. PMID: 18210741.Peer-Reviewed Original ResearchConceptsHepatic stellate cellsBile duct ligationLiver fibrosisDuct ligationPurinergic receptorsCommon bile duct ligationEffect of PPADSPurinergic receptor inhibitorsDevelopment of cirrhosisHSC proliferationEffective pharmacologic treatmentExperimental liver fibrosisAnnexin V flow cytometryEffect of suraminSirius red stainQuantitative RT-PCRPharmacologic treatmentReceptor inhibitorsPPADSStellate cellsLiver sectionsFibrosisBromodeoxyuridine uptakePurinoceptor activationExperimental animals
2005
Secretion of MCP-1/CCL2 by bile duct epithelia induces myofibroblastic transdifferentiation of portal fibroblasts
Kruglov EA, Nathanson RA, Nguyen T, Dranoff JA. Secretion of MCP-1/CCL2 by bile duct epithelia induces myofibroblastic transdifferentiation of portal fibroblasts. AJP Gastrointestinal And Liver Physiology 2005, 290: g765-g771. PMID: 16282363, DOI: 10.1152/ajpgi.00308.2005.Peer-Reviewed Original ResearchConceptsBile duct epitheliumHepatic stellate cellsPortal fibroblastsMCP-1Biliary fibrosisDuct epitheliumMyofibroblastic transdifferentiationMCP-1/CCL2Fibrogenic liver cellsChemoattractant protein-1Ectonucleotidase NTPDase2PF proliferationAlpha-SMA levelsReceptor CCR2Stellate cellsParacrine fashionFunctional receptorsInduces proliferationImportant mediatorMuscle expressionFibrosisLiver cellsProtein 1Procollagen productionRecent evidence
2004
Autocrine release of TGF‐β by portal fibroblasts regulates cell growth
Wells RG, Kruglov E, Dranoff JA. Autocrine release of TGF‐β by portal fibroblasts regulates cell growth. FEBS Letters 2004, 559: 107-110. PMID: 14960316, DOI: 10.1016/s0014-5793(04)00037-7.Peer-Reviewed Original ResearchConceptsHepatic stellate cellsPortal fibroblastsBiliary fibrosisGrowth factorTGF-beta2Activated hepatic stellate cellsDerived growth factorTGF-beta receptorsFibroblast growth factorPF proliferationMyofibroblast populationStellate cellsFibrogenic cellsKey growth factorsAutocrine releaseFibrosisCell growthFibroblastsCellsPopulationFactorsTGFLiverReceptors